This editorial refers to 'Peroxynitrite-dependent activation of protein phosphatase type 2A mediates microvascular endothelial barrier dysfunction' by Wu and Wilson, 1 pp. 38-45, this issue.
Recent studies have identified many important signalling pathways that regulate endothelial cell (EC) barrier functions during physiological and pathological conditions. Understanding how these signalling pathways target their downstream effectors and thereby coordinate changes in EC cytoskeleton, junctional adhesion molecules and integrins to regulate EC barrier functions has been the focus of many recent studies. An interesting study by Wu and Wilson addresses the role of protein phosphatase 2A (PP2A) in regulating microvascular EC barrier dysfunction induced by LPS plus interferon (IFNg). 1 The authors used mouse skeletal microvascular ECs and demonstrate that PP2A is required for the development of EC barrier dysfunction induced by LPS plus IFNg. Moreover, the investigators presented a series of carefully conducted biochemical analyses showing that LPS plus IFNg cause an increase in the activity of PP2A, tyrosine nitration of the catalytic subunit of PP2A (PP2Ac), and a decrease in tyrosine phosphorylation of PP2Ac, in a manner that depends on NADPH oxidase and inducible NO synthase (iNOS). These data raise the hypothesis that peroxynitrite targets PP2Ac by inducing its tyrosine nitration, a response that correlates with decreased tyrosine phosphorylation of PP2Ac and increases in its activity. The experiments using exogenous peroxynitrite supported this hypothesis: peroxynitrite induced tyrosine nitration of PP2Ac, decreased tyrosine phosphorylation of PP2Ac, enhanced PP2Ac activity, and increased EC permeability. These data suggest that PP2Ac is a downstream target of peroxynitrite generated by LPS plus IFNg and plays important roles in regulating EC barrier dysfunction.
This study carefully examined the activity of PP2A in ECs and presented several novel and interesting findings. These data also underline the importance of defining the uniqueness of signalling pathways in primary ECs. Although PP2A has been extensively studied during cell transformation and apoptosis in many other cell types, relatively little is known about the role of PP2A in regulating EC functions. PP2A is a ubiquitously expressed serine/threonine phosphatase that is composed of a catalytic subunit (PP2Ac), a scaffold subunit (A subunit), and a regulatory subunit (B subunit). The A subunit is structurally flexible and links PP2Ac with many B subunits to form more than 60 different heterotrimeric PP2A holoenzymes that can dephosphorylate many phosphoproteins. 2 Posttranslational modification such as phosphorylation or methylation of the PP2A subunits regulates PP2A complex formation and its activity.
3-5 Deletion of PP2A catalytic or scaffold subunits results in embryonic lethality and cell death. 6, 7 Interestingly, in skeletal microvascular ECs, the basal PP2A activity is low, despite the abundance of the protein. 1 This low PP2A activity correlates with tyrosine phosphorylation of PP2Ac. Treatment with LPS plus IFNg causes a decrease in the tyrosine phosphorylation of PP2Ac and an increase in PP2A activity. These carefully conducted experiments clearly demonstrate the uniqueness of PP2A activity in ECs, both basally and following stimulation with LPS plus IFNg, and also invite future studies to address questions such as: what phosphorylate(s) and dephosphorylate(s) PP2Ac? What is the function of PP2Ac tyrosine phosphorylation? Src family tyrosine kinases such as v-Src and p56lck or growth factor receptors have been shown to phosphorylate PP2Ac on tyrosine residues. 8, 9 This induced PP2A activity by LPS plus IFNg is clearly functionally important in regulating EC barrier dysfunction since inhibition of PP2A activity using a pharmacological inhibitor or inhibition of PP2Ac protein expression using siRNA prevents permeability increases. The fact that these ECs have low PP2A activity before stimulation may explain why siRNA targeting PP2A alone has little effect on the baseline activity of PP2A or the permeability of ECs. This may also explain the seemingly contradicting results from studies in which overexpression of PP2Aa and PP2Ac by adenoviral infection prevents thrombin-induced EC barrier dysfunction and gap formation. 10 Another novel finding from this study is that PP2A is a downstream target of peroxynitrite. The levels of peroxynitrite and nitrotyrosine increase in many models of inflammation where nitric oxide and superoxide are released in large amounts by cells such as the infiltrating inflammatory cells. Peroxynitrite causes cell damage by oxidation and nitration of amino acids in protein, such as converting cysteine to cystine and causing nitration of tyrosine to form nitrotyrosine. Exogenous peroxynitrite causes nitration of actin, b-catenin, a molecular component of the VE cadherin complex, and increases in EC permeability. 11, 12 Cytokine-stimulated ECs also produce peroxynitrite through iNOS or eNOS-derived nitric oxide and NADPH oxidase or xanthine oxidase-derived superoxide. 11 Therefore, identifying downstream targets of peroxynitrite in mediating increases in EC permeability is highly relevant to understanding the pathogenesis of EC injury during inflammatory disorders. This study shows that PP2A is a downstream target of peroxynitrite. Not only does exogenous peroxynitrite cause tyrosine nitration of PP2A and an increase in PP2A activity, but endogenous peroxynitrite induced by LPS plus IFNg targets PP2A in a manner that depends on NADPH oxidase and iNOS.
This study identified PP2A as a novel link between peroxynitrite and cytokine-induced EC barrier dysfunction. More importantly, it also raises many exciting questions for future studies. How does PP2Ac tyrosine nitration and tyrosine phosphorylation influence the interactions of PP2Ac with the other two subunits, subcellular localization of PP2A, and proximity of PP2A to its substrates? How does PP2A regulate EC barrier dysfunction? This study, which clearly defines the functions of PP2A in cytokine-induced EC barrier dysfunction, provides a strong rationale for future studies to test the function of this enzyme in ECs during inflammatory disorders in vivo. A deficiency in PP2Ac is embryonically lethal. However, an effort to define the functional relevance of PP2A in EC injury and oedema formation using an EC-specific knockout mouse model is certainly justified based on the findings in this study.
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